Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
This trial is active, not recruiting.
|Conditions||thyroid cancer, papillary microcarcinoma|
|Sponsor||Memorial Sloan Kettering Cancer Center|
|Start date||June 2011|
|End date||June 2017|
|Trial size||60 participants|
|Trial identifier||NCT01392222, 11-108|
The purpose of this study is to understand more about why some patients choose to have surgery to treat their papillary microcarcinoma (PMC) and others choose to have their papillary microcarcinoma (PMC) regularly watched by their doctor to see if and when they may need surgery (referred to as "active surveillance"). The investigators also hope learn more about what patients and their family members worry about or feel they will gain from surgery or active surveillance.
To explore patients' and families' perceived risks and benefits of active surveillance and surgery within the context of papillary microcarcinoma.
time frame: 5 years
To examine the factors in patients' and families' decision making about the treatment of papillary microcarcinoma.
time frame: 5 years
Male or female participants at least 18 years old.
- Thyroid cancer patients who have been diagnosed with papillary microcarcinoma (or subcentimeter thyroid lesions with fine needle aspiration biopsy suspicious for papillary or follicular thyroid cancer) within the prior 6-12 months as per EMR path report and clinician assessment;
- Presented with the option of treating their papillary microcarcinomas with either surgery or active surveillance as per treating physician;
- 18 years of age or older; Patient-designated significant other eligibility will include:
- Nomination by patient as individual who assisted patient in decision-making regarding how to treat thyroid papillary microcarcinoma;
- 18 years of age or older;
- Thyroid cancer patients with known loco-regional or distant metastases prior to initial surgical intervention as per path report.
|Official title||Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others|
|Principal investigator||Smita Banerjee, PhD|
Call for more information